Page last updated: 2024-10-16

carbamates and Opportunistic Infections

carbamates has been researched along with Opportunistic Infections in 1 studies

Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tavel, JA	1
Babiker, A	1
Fox, L	1
Gey, D	1
Lopardo, G	1
Markowitz, N	1
Paton, N	1
Wentworth, D	1
Wyman, N	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
STALWART: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 With and Without Concomitant Antiretroviral Therapy in Patients With HIV-1 Infection and CD4+ Cell Counts of 300 Cells/mm3 or More[NCT00110812]			Phase 2	267 participants (Actual)	Interventional	2005-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CD4+ Cell Count 2 Years Post-study

(NCT00110812)
Timeframe: two years following close of main study

Intervention	cell/mm^3 (Mean)
IL-2	499.9
Control	557.2

Change in CD4 T Lymphocyte Count

change from baseline to month 12 in CD4 T lymphocyte count (NCT00110812)
Timeframe: At Month 12

Intervention	cell/mm^3 (Mean)
No IL-2	-8.4
IL-2 Without ART	59.0
IL-2 With Pericycle HAART	49.8

Change in HIV-RNA Copies/ml (log10) From Baseline to Month 12

(NCT00110812)
Timeframe: month 12

Intervention	copies/ml (log 10) (Mean)
No IL-2	-0.64
IL-2 Without ART	-0.28
IL-2 With Pericycle HAART	-0.09

Commencement of Continuous Antiretroviral Treatment

Number of patients commencing continuous antiretroviral treatment. (NCT00110812)
Timeframe: from randomization through February 28, 2011, the end of the extension phase

Intervention	participants (Number)
IL-2	108
Control	66

Discontinuation of IL-2

Patients receiving fewer than 3 cycles of IL-2 by week 32 (NCT00110812)
Timeframe: week 32

Intervention	participants (Number)
IL-2 Without ART	12
IL-2 With Pericycle HAART	32

Disease Progression or Death

occurrence of an opportunistic event (AIDS-defining infection or malignancy) or death (NCT00110812)
Timeframe: throughout study, through Feb 28 2009 (median followup of 19 months)

Intervention	participants (Number)
No IL-2	1
IL-2 Without ART	5
IL-2 With Pericycle HAART	7

Fasting Lipid Profile

total fasting cholesterol (NCT00110812)
Timeframe: week 32

Intervention	mg/dl (Mean)
No IL-2	173.4
IL-2 Without ART	167.0
IL-2 With Pericycle HAART	164.6

HIV-1 Genotype Changes

Patients who developed mutations associated with antiretroviral drugs. (NCT00110812)
Timeframe: after 3rd cycle of IL-2

Intervention	participants (Number)
IL-2 With Pericycle HAART	2

Initiation of Continuous ART

While patients were not taking ART at baseline or while undergoing IL-2 cycles (other than use of pericycle ART in one of the three groups), some chose to start an ART regimen during the study. (NCT00110812)
Timeframe: from randomization through February 28, 2009

Intervention	participants (Number)
No IL-2	34
IL-2 Without ART	23
IL-2 With Pericycle HAART	14

Mean Change in CD4+ T Lymphocyte Count

Change in CD4 count from baseline to week 32. (NCT00110812)
Timeframe: Week 32

Intervention	cell/mm^3 (Mean)
No IL-2	-21.8
IL-2 Without ART	113.7
IL-2 With Pericycle HAART	110.4

Opportunistic Disease or Death During the Trial Extension Phase

Incidence of an opportunistic event (AIDS-defining infection or malignancy) or death between February 28, 2009, when the main study ended, and February 28, 2011, when the extended phase was completed. (NCT00110812)
Timeframe: two years following close of main study

Intervention	participants (Number)
IL-2	8
Control	3

Plasma HIV RNA

change from baseline in HIV-RNA copies/ml (log10) (NCT00110812)
Timeframe: At Week 32

Intervention	copies/ml (log 10) (Mean)
No IL-2	-.39
IL-2 Without ART	-.07
IL-2 With Pericycle HAART	-.01

SGOT

Number of participants with aspartate aminotransferase (SGOT) greater than 5 times the upper limit of normal (NCT00110812)
Timeframe: week 32

Intervention	participants (Number)
No IL-2	1
IL-2 Without ART	0
IL-2 With Pericycle HAART	0

Thyroid Stimulating Hormone

Number of participants with thyroid stimulating hormone greater than the upper limit of normal (NCT00110812)
Timeframe: week 32

Intervention	participants (Number)
No IL-2	3
IL-2 Without ART	2
IL-2 With Pericycle HAART	7

Undetectable HIV-RNA

Patients with undetectable HIV-RNA levels measured at 24 months after the close of the main study, at the end of the extension phase. (NCT00110812)
Timeframe: 24 months post-trial

Intervention	participants (Number)
IL-2	97
Control	60

Trials

1 trial available for carbamates and Opportunistic Infections

Article	Year
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PloS one, 2010, Feb-23, Volume: 5, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Sc	2010